CO2020013571A2 - Formulaciones estables de anticuerpos terapéuticos - Google Patents
Formulaciones estables de anticuerpos terapéuticosInfo
- Publication number
- CO2020013571A2 CO2020013571A2 CONC2020/0013571A CO2020013571A CO2020013571A2 CO 2020013571 A2 CO2020013571 A2 CO 2020013571A2 CO 2020013571 A CO2020013571 A CO 2020013571A CO 2020013571 A2 CO2020013571 A2 CO 2020013571A2
- Authority
- CO
- Colombia
- Prior art keywords
- therapeutic antibodies
- stable formulations
- formulation
- stable
- devoid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841013647 | 2018-04-10 | ||
| PCT/IN2019/050293 WO2019198101A1 (en) | 2018-04-10 | 2019-04-10 | Stable formulations of therapeutic antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020013571A2 true CO2020013571A2 (es) | 2021-01-18 |
Family
ID=68164106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0013571A CO2020013571A2 (es) | 2018-04-10 | 2020-10-28 | Formulaciones estables de anticuerpos terapéuticos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12433947B2 (enExample) |
| EP (1) | EP3773696A4 (enExample) |
| JP (1) | JP2021521171A (enExample) |
| CN (1) | CN112292146A (enExample) |
| AU (1) | AU2019251453A1 (enExample) |
| BR (1) | BR112020020703A2 (enExample) |
| CO (1) | CO2020013571A2 (enExample) |
| SG (1) | SG11202009876TA (enExample) |
| WO (1) | WO2019198101A1 (enExample) |
| ZA (1) | ZA202006264B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202012778YA (en) | 2015-12-18 | 2021-01-28 | Astellas Pharma Inc | Pharmaceutical composition comprising anti-human tslp receptor antibody |
| WO2019198099A1 (en) * | 2018-04-10 | 2019-10-17 | Dr. Reddy's Laboratories Limited | Stable antibody formulation |
| WO2024098180A1 (en) * | 2022-11-07 | 2024-05-16 | Wuxi Biologics (Hong Kong) Limited | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same |
| EP4259192A4 (en) * | 2020-12-09 | 2024-11-20 | Dr. Reddy's Laboratories Limited | STABLE AQUEOUS BUFFER-FREE FORMULATION OF AN INTEGRIN ANTIBODY |
| EP4346899A1 (en) * | 2021-06-04 | 2024-04-10 | Polpharma Biologics S.A. | Vedolizumab formulation |
| EP4717712A2 (en) * | 2021-12-27 | 2026-04-01 | Polpharma Biologics S.A. | Vedolizumab formulation |
| TW202432601A (zh) | 2022-11-07 | 2024-08-16 | 美商上游生物公司 | 包含抗人類ｔｓｌｐ受體抗體之醫藥組成物及其使用方法 |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2236154T3 (en) | 2003-02-10 | 2018-06-25 | Biogen Ma Inc | IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT |
| NZ595526A (en) * | 2007-06-14 | 2013-03-28 | Biogen Idec Inc | Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| BRPI0820819B1 (pt) * | 2007-12-21 | 2021-06-08 | F. Hoffmann-La Roche Ag | formulação de anticorpos humanizados b-ly 1 e seu uso |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| MX367097B (es) * | 2011-05-02 | 2019-08-05 | Millennium Pharm Inc | FORMULACION PARA ANTICUERPO ANTI-A4ß7. |
| TWI752912B (zh) | 2015-07-17 | 2022-01-21 | 美商寇西勒斯生物科技股份有限公司 | 那他珠單抗的穩定水性調配物 |
| CN114375307B (zh) | 2019-06-10 | 2025-12-05 | 武田药品工业株式会社 | 产生抗α4β7抗体的方法 |
-
2019
- 2019-04-10 US US17/045,406 patent/US12433947B2/en active Active
- 2019-04-10 SG SG11202009876TA patent/SG11202009876TA/en unknown
- 2019-04-10 JP JP2020555466A patent/JP2021521171A/ja active Pending
- 2019-04-10 BR BR112020020703-9A patent/BR112020020703A2/pt not_active IP Right Cessation
- 2019-04-10 AU AU2019251453A patent/AU2019251453A1/en not_active Abandoned
- 2019-04-10 EP EP19785714.7A patent/EP3773696A4/en active Pending
- 2019-04-10 CN CN201980038006.9A patent/CN112292146A/zh active Pending
- 2019-04-10 WO PCT/IN2019/050293 patent/WO2019198101A1/en not_active Ceased
-
2020
- 2020-10-08 ZA ZA2020/06264A patent/ZA202006264B/en unknown
- 2020-10-28 CO CONC2020/0013571A patent/CO2020013571A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3773696A1 (en) | 2021-02-17 |
| CN112292146A (zh) | 2021-01-29 |
| JP2021521171A (ja) | 2021-08-26 |
| US12433947B2 (en) | 2025-10-07 |
| US20210401982A1 (en) | 2021-12-30 |
| WO2019198101A1 (en) | 2019-10-17 |
| ZA202006264B (en) | 2022-09-28 |
| BR112020020703A2 (pt) | 2021-01-12 |
| EP3773696A4 (en) | 2021-12-29 |
| AU2019251453A2 (en) | 2020-12-03 |
| AU2019251453A1 (en) | 2020-11-26 |
| SG11202009876TA (en) | 2020-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020013571A2 (es) | Formulaciones estables de anticuerpos terapéuticos | |
| CL2020002012A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032) | |
| CO2019011021A2 (es) | Formulacion estable de anticuerpos | |
| MX2025010757A (es) | Formulacion farmaceutica de ph bajo | |
| JOP20210229A1 (ar) | صيغة جسم مضاد علاجي | |
| CO2020013552A2 (es) | Formulación de anticuerpos | |
| CR20190400A (es) | Formulaciones de anticuerpo monoclonal anti-vrs | |
| WO2018075692A3 (en) | Antibody constructs | |
| CO2020016008A2 (es) | Formulación de proteína de fusión estable | |
| MX385109B (es) | Formulaciones de anticuerpos. | |
| CL2018000226A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
| BR112016026811A2 (pt) | formulação de anticorpo | |
| MX2018016362A (es) | Formulaciones de anticuerpo anti-cd19. | |
| MX2021004774A (es) | Formulacion de anticuerpos. | |
| CO2022005737A2 (es) | Formulación estable de anticuerpo de integrina | |
| CO2020016014A2 (es) | Formulación de proteína de fusión ctla4-ig | |
| MA54139A (fr) | Formulation d'anticorps | |
| CL2023000486A1 (es) | Formulación farmacéutica que comprende un bite, anticuerpo biespecífico y metionina | |
| MX2023001160A (es) | Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo. | |
| AR113534A1 (es) | Formulación | |
| MX2021005910A (es) | Formulacion de proteina de alta concentracion. | |
| CO2020013545A2 (es) | Formulación estable de anticuerpos | |
| EP3820475A4 (en) | Administration of sumo-activating enzyme inhibitor and anti-cd20 antibodies | |
| CL2023002894A1 (es) | Combinación de un inhibidor de hdac6 y un inhibidor del punto de control de ctla4 | |
| BR112023002984A2 (pt) | Formulações de anticorpo terapêutico |